Skip to content
Companies

Trinity Nuclein Series C QP Investors

Investment vehicle backing a rapid PCR test maker

Raised to date

$1M

of $15M offered across 1 Form D filing

Still open
$14M
Investors
11
Last filed
Mar 3, 2025

About

Trinity Nuclein Series C QP Investors LLC is an investment entity associated with Trinity Investors, a distinguished private equity firm. This vehicle is primarily aimed at funding Nuclein, a biotechnology innovator dedicated to creating advanced rapid diagnostic testing solutions for infectious diseases.

Trinity Nuclein stands out by enabling healthcare providers to obtain rapid, lab-quality diagnostic results in just 15 minutes, significantly reducing the waiting times associated with traditional testing methods.

Funding

  • EquityFiled Mar 3, 2025Form D
    $1M/ $15M

Product

DASH® Rapid PCR System

Rapid Diagnostics

The DASH® Rapid PCR System is a cutting-edge diagnostic tool that delivers highly accurate PCR test results within a mere 15 minutes, suitable for use at the point of care. It addresses the complexities and delays of conventional diagnostic testing by offering rapid and highly reliable results in a variety of healthcare settings.

  • Fast results comparable to traditional antigen tests
  • Low-cost diagnostics with high sensitivity and specificity
  • Robust multiplexing capabilities across different sample types

Built for

Healthcare providers and organizations

People on file